CA2784278C - Wash solution and method for affinity chromatography - Google Patents
Wash solution and method for affinity chromatography Download PDFInfo
- Publication number
- CA2784278C CA2784278C CA2784278A CA2784278A CA2784278C CA 2784278 C CA2784278 C CA 2784278C CA 2784278 A CA2784278 A CA 2784278A CA 2784278 A CA2784278 A CA 2784278A CA 2784278 C CA2784278 C CA 2784278C
- Authority
- CA
- Canada
- Prior art keywords
- arginine
- protein
- wash
- wash solution
- matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001042 affinity chromatography Methods 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 124
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 124
- 150000003839 salts Chemical class 0.000 claims abstract description 74
- 239000004475 Arginine Substances 0.000 claims abstract description 71
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 66
- 238000005406 washing Methods 0.000 claims abstract description 49
- 239000012535 impurity Substances 0.000 claims abstract description 31
- 150000001483 arginine derivatives Chemical class 0.000 claims abstract description 27
- 229960003121 arginine Drugs 0.000 claims description 70
- 239000011159 matrix material Substances 0.000 claims description 54
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
- 238000010828 elution Methods 0.000 claims description 20
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 16
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 11
- 108091006020 Fc-tagged proteins Proteins 0.000 claims description 5
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 claims description 3
- SNEIUMQYRCDYCH-UHFFFAOYSA-N acetylarginine Chemical compound CC(=O)NC(C(O)=O)CCCN=C(N)N SNEIUMQYRCDYCH-UHFFFAOYSA-N 0.000 claims description 3
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 claims description 3
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- 101710120037 Toxin CcdB Proteins 0.000 claims description 2
- 229960003589 arginine hydrochloride Drugs 0.000 claims description 2
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 claims 1
- 239000013628 high molecular weight specie Substances 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 171
- 238000000746 purification Methods 0.000 description 30
- 239000000872 buffer Substances 0.000 description 23
- 230000009467 reduction Effects 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000003306 harvesting Methods 0.000 description 13
- 239000007790 solid phase Substances 0.000 description 13
- 230000027455 binding Effects 0.000 description 12
- 239000007983 Tris buffer Substances 0.000 description 11
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 11
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 238000011067 equilibration Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 5
- 235000019800 disodium phosphate Nutrition 0.000 description 5
- 229910000397 disodium phosphate Inorganic materials 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- -1 halogen salt Chemical class 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000004811 liquid chromatography Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 4
- 239000012504 chromatography matrix Substances 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 102000000584 Calmodulin Human genes 0.000 description 3
- 108010041952 Calmodulin Proteins 0.000 description 3
- 241000223782 Ciliophora Species 0.000 description 3
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OGGXGZAMXPVRFZ-UHFFFAOYSA-N dimethylarsinic acid Chemical compound C[As](C)(O)=O OGGXGZAMXPVRFZ-UHFFFAOYSA-N 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000013627 low molecular weight specie Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- CROYZNIEESCKGY-UHFFFAOYSA-N 1-(5-methoxy-4-methyl-2-methylsulfanylphenyl)propan-2-amine Chemical compound COC1=CC(CC(C)N)=C(SC)C=C1C CROYZNIEESCKGY-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- FOUZISDNESEYLX-UHFFFAOYSA-N 2-(2-hydroxyethylazaniumyl)acetate Chemical compound OCCNCC(O)=O FOUZISDNESEYLX-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- TXUWMXQFNYDOEZ-UHFFFAOYSA-N 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylidene-4-imidazolidinone Chemical compound O=C1N(C)C(=S)NC1CC1=CNC2=CC=CC=C12 TXUWMXQFNYDOEZ-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- NDYLCHGXSQOGMS-UHFFFAOYSA-N CL-20 Chemical compound [O-][N+](=O)N1C2N([N+]([O-])=O)C3N([N+](=O)[O-])C2N([N+]([O-])=O)C2N([N+]([O-])=O)C3N([N+]([O-])=O)C21 NDYLCHGXSQOGMS-UHFFFAOYSA-N 0.000 description 1
- 241000272165 Charadriidae Species 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
- 101100185024 Mus musculus Mslnl gene Proteins 0.000 description 1
- 125000001099 N(omega)-arginino group Chemical group 0.000 description 1
- RAQQRQCODVNJCK-JLHYYAGUSA-N N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-[(E)-5-hydroxy-3-(2-hydroxyethyldisulfanyl)pent-2-en-2-yl]formamide Chemical compound C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSCCO RAQQRQCODVNJCK-JLHYYAGUSA-N 0.000 description 1
- 101150071716 PCSK1 gene Proteins 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001410206 Protella Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000012436 analytical size exclusion chromatography Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 1
- 235000019846 buffering salt Nutrition 0.000 description 1
- 229950004243 cacodylic acid Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- VDEGQTCMQUFPFH-UHFFFAOYSA-N hydroxy-dimethyl-arsine Natural products C[As](C)O VDEGQTCMQUFPFH-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- FBEVECUEMUUFKM-UHFFFAOYSA-M tetrapropylazanium;chloride Chemical compound [Cl-].CCC[N+](CCC)(CCC)CCC FBEVECUEMUUFKM-UHFFFAOYSA-M 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28805909P | 2009-12-18 | 2009-12-18 | |
| US61/288,059 | 2009-12-18 | ||
| PCT/EP2010/070076 WO2011073389A1 (en) | 2009-12-18 | 2010-12-17 | Wash solution and method for affinity chromatography |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2784278A1 CA2784278A1 (en) | 2011-06-23 |
| CA2784278C true CA2784278C (en) | 2019-02-26 |
Family
ID=43598315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2784278A Active CA2784278C (en) | 2009-12-18 | 2010-12-17 | Wash solution and method for affinity chromatography |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9505803B2 (enExample) |
| EP (2) | EP2513134B1 (enExample) |
| JP (2) | JP5909450B2 (enExample) |
| KR (1) | KR101858266B1 (enExample) |
| CN (1) | CN102725304B (enExample) |
| AU (1) | AU2010332778B2 (enExample) |
| BR (1) | BR112012014937B1 (enExample) |
| CA (1) | CA2784278C (enExample) |
| DK (2) | DK3272764T3 (enExample) |
| ES (2) | ES2651065T3 (enExample) |
| IL (1) | IL220164B (enExample) |
| LT (2) | LT2513134T (enExample) |
| MX (1) | MX2012007103A (enExample) |
| PL (2) | PL3272764T3 (enExample) |
| PT (2) | PT3272764T (enExample) |
| RU (1) | RU2564569C2 (enExample) |
| SG (2) | SG181771A1 (enExample) |
| WO (1) | WO2011073389A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| EP2500413A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| US8895709B2 (en) | 2008-10-20 | 2014-11-25 | Abbvie Inc. | Isolation and purification of antibodies using protein A affinity chromatography |
| NZ592097A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Viral inactivation during purification of il-12 and il-18 antibodies |
| DK3272764T3 (da) * | 2009-12-18 | 2024-05-06 | Novartis Ag | Fremgangsmåde til affinitetskromatografi |
| AU2011208659B2 (en) * | 2010-01-22 | 2015-05-28 | Boehringer Ingelheim International Gmbh | Chromatographic method for purifying Fc-containing proteins |
| PL2714714T3 (pl) * | 2011-06-01 | 2018-11-30 | Novartis Ag | Roztwór do przemywania i sposób chromatografii powinowactwa |
| MX359384B (es) | 2011-10-11 | 2018-09-25 | Genentech Inc | Conjunto mejorado de anticuerpos bisespecificos. |
| CA2910065C (en) * | 2013-05-15 | 2023-09-19 | Medimmune Limited | Purification of recombinantly produced polypeptides |
| CN105848746B (zh) * | 2013-09-05 | 2019-07-09 | 豪夫迈·罗氏有限公司 | 用于层析重复利用的方法 |
| US9546208B2 (en) | 2014-01-03 | 2017-01-17 | Bio-Rad Laboratories, Inc. | Removal of impurities from protein A eluates |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10695693B2 (en) | 2015-03-13 | 2020-06-30 | Bristol-Myers Squibb Company | Use of alkaline washes during chromatography to remove impurities |
| SI3337812T1 (sl) | 2015-08-21 | 2021-08-31 | F. Hoffmann-La Roche Ag | Postopek za zmanjševanje beljakovin gostiteljske celice v afinitetni kromatografiji |
| CN107849122B (zh) * | 2015-08-21 | 2022-01-25 | 豪夫迈·罗氏有限公司 | 用低电导率洗涤缓冲液进行亲和层析纯化 |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP6987424B2 (ja) | 2016-05-11 | 2022-01-05 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを洗浄および／または消毒する方法 |
| WO2017194597A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| CN109311949B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 储存分离基质的方法 |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| KR102359192B1 (ko) * | 2016-07-25 | 2022-02-04 | 세파론, 인코포레이티드 | 친화성 크로마토그래피 세정 완충액 |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| CN111344410B (zh) | 2017-08-17 | 2023-09-15 | 济世易为生物有限公司 | 从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法 |
| CN107793469B (zh) * | 2017-10-16 | 2021-07-30 | 上海药明生物技术有限公司 | 一种去除宿主细胞蛋白含量的亲和纯化工艺 |
| SG11202005809TA (en) * | 2017-12-21 | 2020-07-29 | Genzyme Corp | Methods for enhanced removal of impurities during protein a chromatography |
| CN111902720B (zh) | 2018-03-21 | 2025-02-07 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
| MX2020010320A (es) | 2018-04-02 | 2021-01-08 | Amgen Inc | Composiciones de erenumab y usos de las mismas. |
| US11612885B2 (en) * | 2018-05-08 | 2023-03-28 | Waters Technologies Corporation | Methods, compositions and kits useful for pH gradient cation exchange chromatography |
| CN112566920A (zh) * | 2018-08-14 | 2021-03-26 | 百时美施贵宝公司 | 改善的蛋白质回收 |
| JP2022551837A (ja) * | 2019-10-08 | 2022-12-14 | ノース カロライナ ステート ユニバーシティ | 免疫グロブリン精製ペプチド、及びその使用 |
| WO2021191684A1 (en) * | 2020-03-27 | 2021-09-30 | Haemalogix Pty Ltd | Composition and method |
| US20230143163A1 (en) * | 2020-04-27 | 2023-05-11 | Alexion Pharmaceuticals, Inc. | Protein a chromatography purification of an antibody |
| CN112827217A (zh) * | 2020-12-29 | 2021-05-25 | 苏州良辰生物医药科技有限公司 | 一种层析柱清洗液及其应用 |
| KR20250121073A (ko) * | 2022-12-12 | 2025-08-11 | 하. 룬드벡 아크티에셀스카브 | 단백질 정제에서 아르기닌 세척 |
| WO2024233992A2 (en) * | 2023-05-11 | 2024-11-14 | Trophogen, Inc. | Methods of manufacturing highly glycosylated glycoprotein hormones and their analogs |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704366A (en) | 1984-06-22 | 1987-11-03 | Bio-Rad Laboratories, Inc. | Process for binding IgG to protein A |
| US4857320A (en) * | 1987-02-19 | 1989-08-15 | Monsanto Company | Method of enhancing the solubility of tissue plasminogen activator |
| JPH01238534A (ja) * | 1988-03-17 | 1989-09-22 | Mitsui Toatsu Chem Inc | エンドトキシンの除去方法 |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| ES2293661T3 (es) | 1996-11-27 | 2008-03-16 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteinas a. |
| AU760048B2 (en) | 1998-05-06 | 2003-05-08 | Genentech Inc. | Protein purification by ion exchange chromatography |
| CA2333747C (en) | 1998-06-01 | 2008-02-19 | Genentech, Inc. | Separation of protein monomers by use of ion-exchange chromatography |
| WO2002072615A1 (en) | 2001-03-09 | 2002-09-19 | Chugai Seiyaku Kabushiki Kaisha | Method of purifying protein |
| ATE421536T1 (de) | 2001-06-05 | 2009-02-15 | Genetics Inst Llc | Verfahren zur reinigung stark anionischer proteine |
| AU2003210802B2 (en) | 2002-02-05 | 2009-09-10 | Genentech Inc. | Protein purification |
| DK1561756T3 (en) | 2002-09-11 | 2016-02-15 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR CLEANING PROTEIN. |
| CA2503284A1 (en) * | 2002-10-24 | 2004-05-06 | Enos Pharmaceuticals, Inc. | Sustained release l-arginine formulations and methods of manufacture and use |
| EP1575516B1 (en) * | 2002-11-26 | 2012-05-30 | Abbott Biotherapeutics Corp. | Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis |
| US20040224886A1 (en) * | 2003-01-08 | 2004-11-11 | Chiron Corporation | Stabilized compositions comprising tissue factor pathway inhibitor protein or tissue factor pathway inhibitor variant proteins |
| GB0304576D0 (en) | 2003-02-28 | 2003-04-02 | Lonza Biologics Plc | Protein a chromatography |
| PT1601697E (pt) | 2003-02-28 | 2007-09-04 | Lonza Biologics Plc | Purificação de anticorpos através de proteína a e cromatografia de troca iónica. |
| MXPA06004472A (es) | 2003-10-27 | 2006-06-20 | Wyeth Corp | Eliminacion de agregados de atopeso molecular utilizando cromatografia de hidroxiapatita. |
| US8084032B2 (en) | 2004-01-21 | 2011-12-27 | Ajinomoto Co., Inc. | Purification method which prevents denaturation of an antibody |
| EP1698637B1 (en) | 2005-03-03 | 2008-10-15 | Ajinomoto Co., Inc. | A method for improving recovery yield in protein purification with gel filtration chromatography using arginine |
| ES2797480T3 (es) * | 2005-03-11 | 2020-12-02 | Wyeth Llc | Un procedimiento de cromatografía de reparto débil |
| JP5530633B2 (ja) | 2006-01-06 | 2014-06-25 | イー・エム・デイー・ミリポア・コーポレイシヨン | アフィニティークロマトグラフィーマトリックスおよびその作成および使用法。 |
| US8263750B2 (en) | 2006-03-16 | 2012-09-11 | Amgen Inc. | Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step |
| CA2645739A1 (en) | 2006-03-20 | 2007-09-27 | Medarex, Inc. | Protein purification |
| US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
| BRPI0712496A2 (pt) * | 2006-06-02 | 2012-09-25 | Wyeth Corp | peptìdeo isolado, composição compreendendo o referido peptìdeo, ácido nucléico isolado e métodos de purificar uma proteìna na superfamìlia do fator beta de transformação do crescimento (tgf-?) e de estabilizar uma solução contendo uma proteìna na superfamìlia tgf-b. |
| WO2008025748A1 (en) | 2006-08-28 | 2008-03-06 | Ares Trading S.A. | Process for the purification of fc-containing proteins |
| US8350013B2 (en) * | 2006-09-08 | 2013-01-08 | Wyeth Llc | Arginine wash in protein purification using affinity chromatography |
| US8168185B2 (en) | 2007-01-17 | 2012-05-01 | Merck Serono Sa | Process for the purification of anti CD-25 antibodies |
| JP5064558B2 (ja) | 2007-06-01 | 2012-10-31 | エフ．ホフマン−ラ ロシュ アーゲー | 免疫グロブリン精製 |
| CN103396480A (zh) | 2008-05-15 | 2013-11-20 | 诺沃—诺迪斯克有限公司 | 抗体纯化方法 |
| MX2011001696A (es) | 2008-08-14 | 2011-03-25 | Merck Sharp & Dohme | Metodos para purificar anticuerpos usando cromatografia de afinidad con proteina a. |
| DK3272764T3 (da) | 2009-12-18 | 2024-05-06 | Novartis Ag | Fremgangsmåde til affinitetskromatografi |
| PL2714714T3 (pl) * | 2011-06-01 | 2018-11-30 | Novartis Ag | Roztwór do przemywania i sposób chromatografii powinowactwa |
-
2010
- 2010-12-17 DK DK17188657.5T patent/DK3272764T3/da active
- 2010-12-17 PT PT171886575T patent/PT3272764T/pt unknown
- 2010-12-17 PL PL17188657.5T patent/PL3272764T3/pl unknown
- 2010-12-17 RU RU2012130151/10A patent/RU2564569C2/ru active
- 2010-12-17 CN CN201080057457.6A patent/CN102725304B/zh active Active
- 2010-12-17 SG SG2012044707A patent/SG181771A1/en unknown
- 2010-12-17 DK DK10790452.6T patent/DK2513134T3/en active
- 2010-12-17 WO PCT/EP2010/070076 patent/WO2011073389A1/en not_active Ceased
- 2010-12-17 AU AU2010332778A patent/AU2010332778B2/en active Active
- 2010-12-17 ES ES10790452.6T patent/ES2651065T3/es active Active
- 2010-12-17 CA CA2784278A patent/CA2784278C/en active Active
- 2010-12-17 EP EP10790452.6A patent/EP2513134B1/en not_active Revoked
- 2010-12-17 BR BR112012014937-7A patent/BR112012014937B1/pt active IP Right Grant
- 2010-12-17 KR KR1020127015524A patent/KR101858266B1/ko active Active
- 2010-12-17 EP EP17188657.5A patent/EP3272764B1/en active Active
- 2010-12-17 LT LTEP10790452.6T patent/LT2513134T/lt unknown
- 2010-12-17 ES ES17188657T patent/ES2982297T3/es active Active
- 2010-12-17 PT PT107904526T patent/PT2513134T/pt unknown
- 2010-12-17 LT LTEP17188657.5T patent/LT3272764T/lt unknown
- 2010-12-17 SG SG10201408384PA patent/SG10201408384PA/en unknown
- 2010-12-17 MX MX2012007103A patent/MX2012007103A/es unknown
- 2010-12-17 JP JP2012543787A patent/JP5909450B2/ja active Active
- 2010-12-17 PL PL10790452T patent/PL2513134T3/pl unknown
- 2010-12-17 US US13/516,960 patent/US9505803B2/en active Active
-
2012
- 2012-06-04 IL IL220164A patent/IL220164B/en active IP Right Grant
-
2016
- 2016-02-08 JP JP2016021798A patent/JP2016128495A/ja active Pending
- 2016-10-28 US US15/336,878 patent/US20170044211A1/en not_active Abandoned
-
2019
- 2019-03-25 US US16/363,170 patent/US20190233469A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2784278C (en) | Wash solution and method for affinity chromatography | |
| EP2714714B1 (en) | Wash solution and method for affinity chromatography | |
| KR101498771B1 (ko) | 항체의 정제 방법 | |
| US8435527B2 (en) | Purification method which prevents denaturation of an antibody | |
| JP2011525523A5 (enExample) | ||
| US7223848B2 (en) | Methods for purifying Fc-containing proteins | |
| NZ521578A (en) | Methods for purifying highly anionic sulphated proteins comprising an immunoglobulin domain | |
| EP4380948A1 (en) | Method to purify an antibody composition using cation exchange chromatography | |
| JP2014094936A (ja) | 抗体の精製方法 | |
| EP1809664B1 (en) | A novel process for purification of human growth harmone | |
| WO2023007516A1 (en) | Method to control high molecular weight aggregates in an antibody composition | |
| WO2018146067A1 (en) | Process for the purification of soluble psgl-1 protein variants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20151217 |